Validation and clinical utility of OMGRate and MG-QOL15 in evaluating symptoms and quality of life in Chinese patients with ocular myasthenia gravis - Takeaways - MDSpire

Validation and clinical utility of OMGRate and MG-QOL15 in evaluating symptoms and quality of life in Chinese patients with ocular myasthenia gravis

  • By

  • Ting Tang

  • Qiwen Feng

  • Youran Cai

  • Yuying Dong

  • Jian Chen

  • Rijia Zhang

  • Qing Zhou

  • May 22, 2026

  • 0 min

Share

  • 1

    The study evaluated the OMGRate and MG-QOL15 for assessing quality of life in Chinese patients with ocular myasthenia gravis.

  • 2

    A total of 52 patients with ocular myasthenia gravis were included, with assessments at baseline and 1, 3, and 6 months post-treatment.

  • 3

    Significant reductions in OMGRate and MG-QOL15 scores were observed, reaching optimal levels at 6 months post-treatment.

  • 4

    OMG significantly impairs quality of life, and standardized treatment improves both clinical symptoms and patient-reported outcomes.

  • 5

    The OMGRate was validated as an effective method for assessing disease severity in the Chinese ocular myasthenia gravis population.

Original Source(s)

Validation and clinical utility of OMGRate and MG-QOL15 in evaluating symptoms and quality of life in Chinese patients with ocular myasthenia gravis

  • by Ting Tang, Qiwen Feng, Youran Cai, Yuying Dong, Jian Chen, Rijia Zhang, Qing Zhou

  • May 22, 2026

Related Content

Retinal Imaging AI May Flag Brain Health Risk

Authors said AI-driven retinal screening still lacks evidence that it improves patient outcomes.

EYP-1901 for Retinal Exudative Diseases

Updates from the clinical trial program in Wet AMD and DME

Neovascular glaucoma: pathophysiology, diagnosis, and contemporary management